“Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors – A survey"

2020 Yang, 2020, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis, Int J Infect Dis, 94, 91, 10.1016/j.ijid.2020.03.017 Singer, 2020, A call for rational intensive care in the era of COVID-19, Am J Respir Cell Mol Biol, 10.1165/rcmb.2020-0151LE Mehra, 2020, Retraction - hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis, Lancet Liu, 2020, Hydroxychloroquine,a less toxic derivative of chloroquine,is effective in inhibiting SARSCoV-2 infection in vitro, Cell Discov, 6, 16, 10.1038/s41421-020-0156-0 Tang, 2020, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled Trial, BMJ, 369, m1849, 10.1136/bmj.m1849 Hernandez, 2020, Hydroxychloroquine or chloroquine for treatment or prophylaxis of COVID-19: a living systematic review, Ann Intern Med Singh, 2020, Hydroxychloroquine in patients with COVID-19: a systematic review and meta-analysis, Diabetes Metab Syndr, 14, 589, 10.1016/j.dsx.2020.05.017 Burke, 2020, Active monitoring of persons exposed to patients with confirmed COVID-19 — United States, January–February 2020, MMWR Morb Mortal Wkly Rep, 69, 245, 10.15585/mmwr.mm6909e1 Liu, 2020, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov, 6, 16, 10.1038/s41421-020-0156-0 Cohen, 2020, Hydroxychloroquine for the prevention of covid-19 — searching for evidence, N Engl J Med, 10.1056/NEJMe2020388 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 10.1016/j.ijantimicag.2020.105949 Chen, 2020, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv Lee, 2020, Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?, Int J Antimicrob Agents, 10.1016/j.ijantimicag.2020.105988 Boulware, 2020, A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19, N Engl J Med, 10.1056/NEJMoa2016638 Rathi, 2020, Hydroxychloroquine prophylaxis for COVID-19 contacts in India, Lancet Infect Dis, 10.1016/S1473-3099(20)30313-3 ChatterjeeP, Anand T, Singh J, Rasaily R, Singh R, Das S et al. Healthcare workers & SARS-CoV-2 infection in India: a case-control investigation in the time of COVID-19. Indian J Med Res, Epub ahead of print. DOI: 10.4103/ijmr.IJMR_2234_20. Rosenberg ES, Dufort EM, Blog DS. COVID-19 testing, epidemic features, hospital outcomes, and household prevalence, New York State—March 2020. Clin Infect Dis. Published online May 8, 2020. doi:10.1093/cid/ciaa549. Gbinigie, 2020, Should azithromycin be used to treat COVID-19? A rapid review, BJGP Open Singh, 2020, Remdesivir in COVID-19: a critical review of pharmacology, pre-clinical and clinical studies, Diabetes Metab Syndr, 14, 641, 10.1016/j.dsx.2020.05.018 Goldman, 2020, Remdesivir for 5 or 10 Days in patients with severe covid-19, N Engl J Med, 10.1056/NEJMoa2015301 Wu, 2020, An update on current therapeutic drugs treating COVID-19, Curr Pharmacol Rep, 1 Rajendran, 2020, Convalescent plasma transfusion for the treatment of COVID-19: systematic review, J Med Virol, 10.1002/jmv.25961 Gangopadhyay Ghosal